糖尿病：重大新闻！罗格列酮与心血管风险。 - Suppr

Suppr

超能文献

Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.

作者信息

Kaul Sanjay, Diamond George A

机构信息

Division of Cardiology, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.

出版信息

Nat Rev Cardiol. 2010 Dec;7(12):670-2. doi: 10.1038/nrcardio.2010.160.

DOI:10.1038/nrcardio.2010.160

PMID:21102630

Abstract

摘要

相似文献

Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.

Nat Rev Cardiol. 2010 Dec;7(12):670-2. doi: 10.1038/nrcardio.2010.160.

Diabetes: making sense of the rosiglitazone controversy.

Nat Rev Cardiol. 2010 Jul;7(7):366-7. doi: 10.1038/nrcardio.2010.69.

Thiazolidinediones and cardiovascular risk: will the evidence so far available modify treatment strategies for type 2 diabetes?

Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):85-7. doi: 10.1016/j.numecd.2008.01.003. Epub 2008 Feb 15.

Rosiglitazone and cardiovascular risk.

Curr Atheroscler Rep. 2008 Oct;10(5):398-404. doi: 10.1007/s11883-008-0062-7.

Thiazolidinediones and clinical diabetes management: new challenges for the fall of 2007.

South Med J. 2007 Nov;100(11):1063-4. doi: 10.1097/01.smj.0000286755.89206.ac.

Rosiglitazone and the FDA.

N Engl J Med. 2007 Oct 25;357(17):1775-6; author reply 1777. doi: 10.1056/NEJMc076347. Epub 2007 Aug 29.

[Rosiglitazone].

Ugeskr Laeger. 2010 Sep 20;172(38):2631; author reply 2631.

Rosiglitazone and cardiovascular risk.

N Engl J Med. 2007 Aug 30;357(9):938; author reply 939-40.

Rosiglitazone--continued uncertainty about safety.

N Engl J Med. 2007 Jul 5;357(1):63-4. doi: 10.1056/NEJMe078118. Epub 2007 Jun 5.

Rosiglitazone: a thunderstorm from scarce and fragile data.

Ann Intern Med. 2007 Oct 16;147(8):585-7. doi: 10.7326/0003-4819-147-8-200710160-00013.

引用本文的文献

Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

Curr Med Chem. 2011;18(24):3720-8. doi: 10.2174/092986711796642364.

Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis.

J Biol Chem. 2011 Jul 8;286(27):23982-95. doi: 10.1074/jbc.M111.220491. Epub 2011 May 14.

本文引用的文献

Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality.

Arch Intern Med. 2010 Jul 26;170(14):1191-1201. doi: 10.1001/archinternmed.2010.207.

Randomized comparison of the effects of rosiglitazone vs. placebo on peak integrated cardiovascular performance, cardiac structure, and function.

Eur Heart J. 2010 Sep;31(18):2262-70. doi: 10.1093/eurheartj/ehq228. Epub 2010 Jul 2.

Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone.

JAMA. 2010 Jul 28;304(4):411-8. doi: 10.1001/jama.2010.920. Epub 2010 Jun 28.

Simpson's paradox visualized: the example of the rosiglitazone meta-analysis.

BMC Med Res Methodol. 2008 May 30;8:34. doi: 10.1186/1471-2288-8-34.

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death.

Ann Intern Med. 2007 Oct 16;147(8):578-81. doi: 10.7326/0003-4819-147-8-200710160-00182. Epub 2007 Aug 6.

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

N Engl J Med. 2007 Jun 14;356(24):2457-71. doi: 10.1056/NEJMoa072761. Epub 2007 May 21.

A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure.

J Am Coll Cardiol. 2007 Apr 24;49(16):1696-704. doi: 10.1016/j.jacc.2006.10.077. Epub 2007 Apr 6.

Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data.

BMC Med Res Methodol. 2007 Jan 23;7:5. doi: 10.1186/1471-2288-7-5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验